Skip to main content
. 2017 Jun 5;8(40):67218–67226. doi: 10.18632/oncotarget.18365

Figure 5. Hernandezine inhibits LPS-induced ROS production and NF-kB activation.

Figure 5

Stable U937 cells, with scramble control shRNA (“sh-C”), AMPKα shRNA (“shAMPKα”, No.1) or dominant negative AMPKα (T172A, “dnAMPKα”), were treated with LPS (100 ng/mL) or plus hernandezine (30 μM) for indicated time, relative ROS intensity (A) and NFκB activation (B) were tested. * p < 0.05 vs. “C” group.# p < 0.05 vs. LPS only group. ** p < 0.05. Experiments in this figure were repeated three times, and similar results were obtained.